Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Pre-Approval PRO BETA 🟡
Slowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 8/12/2025
4
Total Trials
3
Phase 3
3
Phase 2
4
Recruiting
72
Score
Pipeline by Phase
Phase 3
3
Phase 2
3
Phase 1
1
Therapeutic Focus
Breast Cancer SCLC Prostate Cancer Rectal Cancer
Clinical Trials (4)
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
Started: 6/21/2025
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Started: 8/12/2025
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Started: 8/18/2023
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Started: 12/28/2021
Drug Candidates
Raloxifene - Usual Raloxifene - Study Topotecan - usual Topotecan - study Abiraterone - Usual Abiraterone - Study CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Activity Status:
Slowing
Last Trial Started: 8/12/2025
Last Trial Ended: N/A
Trials (12 months): 0
Completed Trials: 0
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.